Bristol Myers scores accelerated approval in more blood cancers for CAR-T therapy Breyanzi
15 Mar 2024
ImmunotherapyAccelerated ApprovalCell TherapyDrug ApprovalClinical Study
Bristol Myers Squibb is bringing its CAR-T cell therapy to adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, thanks to an accelerated approval from the FDA on Thursday.
The one-time infusion, marketed as Breyanzi, is already approved in the US, Japan and Europe for the second-line treatment of relapsed or refractory large B-cell lymphoma, and in Japan, Europe and Canada for relapsed and refractory large B-cell lymphoma in the third-line setting. This latest expansion is for patients who have received at least two prior lines of therapy.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.